These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28373761)

  • 21. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
    Lip GYH; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Deitelzweig S
    JAMA Netw Open; 2021 Aug; 4(8):e2120064. PubMed ID: 34398204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
    Wang X; Wang T; Chen X; Tian W; Ma D; Zhang J; Li Q; Chen Z; Ju J; Xu H; Chen K
    J Am Med Dir Assoc; 2023 Aug; 24(8):1233-1239.e26. PubMed ID: 37355246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants.
    Morais J; De Caterina R
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):201-14. PubMed ID: 26780749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
    De Caterina R; Ageno W; Agnelli G; Chan NC; Diener HC; Hylek E; Raskob GE; Siegal DM; Verheugt FWA; Lip GYH; Weitz JI
    Thromb Haemost; 2019 Jan; 119(1):14-38. PubMed ID: 30597497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
    Verdecchia P; Angeli F; Lip GY; Reboldi G
    PLoS One; 2014; 9(6):e100478. PubMed ID: 24955573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
    Nielsen PB; Lane DA; Rasmussen LH; Lip GY; Larsen TB
    Clin Res Cardiol; 2015 May; 104(5):418-29. PubMed ID: 25416564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known.
    Ingason AB; Hreinsson JP; Björnsson ES
    Drug Saf; 2022 Dec; 45(12):1449-1456. PubMed ID: 36227528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel anticoagulants: bleeding risk and management strategies.
    Abraham NS; Castillo DL
    Curr Opin Gastroenterol; 2013 Nov; 29(6):676-83. PubMed ID: 24100724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.
    Brodie MM; Newman JC; Smith T; Rockey DC
    Am J Med; 2018 May; 131(5):573.e9-573.e15. PubMed ID: 29175237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT.
    Wojtowicz D; Tomaszuk-Kazberuk A; Małyszko J; Koziński M
    Wiad Lek; 2020; 73(11):2528-2534. PubMed ID: 33454696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
    Liu X; Huang M; Ye C; Zeng J; Zeng C; Ma J
    Medicine (Baltimore); 2020 Jul; 99(27):e21025. PubMed ID: 32629725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.